Company news

Actinogen Medical Limited news in 2021

Actinogen Medical Limited's news releases, calls and decks from 2021, newest first.

View company

Capital Raising Completion

December 19, 2021

ACW Strategic Collaboration with Oxford Uni Researchers

December 6, 2021

XanaMIA Part A trial achieves target enrolment

November 28, 2021

Strategic Update & Capital Raising Investor Presentation

November 24, 2021

Program Expansion & Capital Raising

November 24, 2021

ACW announces open IND for Phase 2 Fragile X trial & LOI

November 8, 2021

R&D Tax Incentive Rebate received of A$1.435 million

October 12, 2021

Actinogen Medical FY21 Results- Progressing the Pipeline

August 30, 2021

Actinogen completes global patent family grant

August 22, 2021

First Patient Enrolled in XanaMIA trial

July 14, 2021

Actinogen receives positive Pre-IND FDA advice for FXS

June 23, 2021

Clinical progress for XanaMIA trial

June 20, 2021

Actinogen Ethics Committee approval for XanaMIA study

June 1, 2021

Response to ASX Price Query

May 24, 2021

Strategic Update & Teleconference Call Notification

April 20, 2021

Actinogen CEO assumes Managing Director position

March 23, 2021

Actinogen appoints Dr Steven Gourlay as CEO

March 14, 2021

ACW raises an addtional $3.55m under a Shortfall Placement

February 10, 2021

Resignation of Dr Bill Ketelbey as Chief Executive Officer

February 8, 2021

FDA Grants ACW Rare Paediatric Disease Designation in FXS

February 4, 2021

Decks in 2021